Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection

Molecular Biology Reports

Volumn 40, Issue 12, 2013, Pages 6899-6911

  Grzegorzewska, Alicja E ^a   Wobszal, Piotr M ^a   Sowińska, Anna ^a   Mostowska, Adrianna ^a   Jagodziński, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Anti HBs; Gene polymorphism; Hemodialysis; Infection; Interleukin 12; Vaccination

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 12P35; INTERLEUKIN 12P40; RECOMBINANT HEPATITIS B VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; CHRONIC GLOMERULONEPHRITIS; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; IL 12A GENE; IL 12B GENE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; RENAL REPLACEMENT THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; YOUNG ADULT;

HEPATITIS B VIRUS;

ADULT; AGED; AGED, 80 AND OVER; DEMOGRAPHY; FEMALE; GENETIC ASSOCIATION STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-12 SUBUNIT P40; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RENAL DIALYSIS; VACCINATION; YOUNG ADULT;

EID: 84890428729     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2809-7     Document Type: Conference Paper

References (68)

1. Morbidity and Mortality Weekly Report (2001) Recommendations for preventing transmission of infections among chronic hemodialysis patients. US Department of Health and Human Services. Centers Dis Control Prev 50:RR-5
2. Nahar K, Jahan M, Nessa A, Tabassum S (2011) Antibody responses after hepatitis B vaccination among maintenance haemodialysis patients. Bangladesh Med Res Counc Bull 37:88-91
3. Idrees MK, Batool S, Ahmed E (2011) Hepatitis B virus among maintainence haemodialysis patients: a report from Karachi, Pakistan. J Pak Med Assoc 61:1210-1214
4. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA et al (2006) Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz 101:689-692. doi: 10.1590/S0074-02762006000600019
5. Cabrerizo M, Bartolomé J, De Sequera P, Caramelo C, Carreńo V (1997) Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 8:1443-1447. doi: 1046-6673/0809-144303.00/0
6. Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M et al (2008) Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 26:4557-4562. doi: 10.1200/JCO.2008.17.3526
7. Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K (2008) Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol 43:849-856
8. Kim MJ, Kwon OS, Chung NS, Lee SY, Jung HS, Park DK et al (2008) The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis [article in Korean]. Korean J Hepatol 14:67-76. doi: 10.3350/kjhep.2008.14.1.67
9. Cendoroglo Neto M, Draibe SA, Silva AE, Ferraz ML, Granato C, Pereira CA et al (1995) Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 10:240-246 not applicable
10. Grzegorzewska AE, Kaczmarek-Leki V, Młot-Michalska M, Niepolski L (2011) Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. Nephrol Dial Transplant 26:970-976. doi: 10.1093/ndt/gfq499
11. Grzegorzewska AE, Kurzawska-Firlej D, Ratajewski W, Frankiewicz D, Niepolski L, Kaczmarek A (2010) Antibodies to core antigen of hepatitis B virus in patients on renal replacement therapy: association with demographic, clinical and laboratory data. Nephron Clin Pract 114:c194-c203. doi: 10.1159/000262302
12. Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R et al (2008) Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob Agents Chemother 52:312-320. doi: 10.1128/AAC.00467-07
13. Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY et al (2010) Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology 138:165-172. doi: 10.1053/j.gastro.2009.09.018
14. Rossol S, Marinos G, Carucci P, Singer MV, Roger W, Naoumov NV (1997) Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 99:3025-3033. doi: 10.1172/JCI119498
15. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT et al (1998) Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 160:1320-1329 0022-1767/98/02.00
16. Schirmbeck R, Reimann J (2001) Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology 44:115-123
17. Kalechman Y, Gafter U, Sobelman D, Sredni B (1990) The effect of a single whole-blood transfusion on cytokine secretion. J Clin Immunol 10:99-105
18. Shaashua L, Sominsky L, Levi B, Sorski L, Reznick M, Page GG et al (2012) In vivo suppression of plasma IL-12 levels by acute and chronic stress paradigms: potential mediating mechanisms and sex differences. Brain Behav Immun 26:996-1005. doi: 10.1016/j.bbi.2012.05.012
19. Kuvibidila S, Warrier RP (2004) Differential effects of iron deficiency and underfeeding on serum levels of interleukin-10, interleukin-12p40, and interferon-gamma in mice. Cytokine 26:73-81
20. Grzybowska EA, Wilczynska A, Siedlecki JA (2001) Regulatory functions of 3′UTRs. Biochem Biophys Res Commun 288:291-295. doi: 10.1006/bbrc.2001. 5738
21. Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J et al (2009) Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res 15:400-405. doi: 10.1158/1078-0432.CCR-08-1829
22. Zwiers A, Seegers D, Heijmans R, Koch A, Hampe J, Nikolaus S et al (2004) Definition of polymorphisms and haplotypes in the interleukin-12B gene: association with IL-12 production but not with Crohn's disease. Genes Immun 5:675-677. doi: 10.1038/sj.gene.6364131
23. Seegers D, Zwiers A, Strober W, Peña AS, Bouma G (2002) A TaqI polymorphism in the 3′UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun 3:419-423. doi: 10.1038/sj.gene.6363919
24. Park JS, Cheong JY, Kang JK, Cho JH, Yu S, Shin HD et al (2007) Association of interleukin-12 gene polymorphism with persistence of hepatitis B virus infection and hepatocellular carcinoma [article in Korean]. Korean J Gastroenterol 50:313-318
25. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA (2004) HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39:978-988. doi: 10.1002/hep.20142
26. Grzegorzewska AE, Wobszal P, Jagodziński PP (2012) Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res 35:1-8. doi: 10.1159/000329932
27. Grzegorzewska AE, Wobszal PM, Mostowska A, Jagodziński PP (2012) Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. BMC Nephrol. doi: 10.1186/1471-2369-13-75
28. Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB (1986) Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 137:315-322
29. Yap I, Guan R, Chan SH (1992) Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein-a preliminary study on immunogenicity. Vaccine 10:439-442
30. European Best Practice Guidelines (2002) Prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant 17(suppl.7):78-87. doi: 10.1093/ndt/17.suppl-7.73
31. Zała̧czniki do rozporza̧dzenia Ministra Zdrowia z dnia 18 kwietnia 2005 r.
32. Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19:376-382
33. Chen J, Liang Z, Lu F, Fang X, Liu S, Zeng Y et al (2011) Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 29:706-711. doi: 10.1016/j.vaccine.2010.11.023
34. Yucesoy B, Sleijffers A, Kashon M, Garssen J, de Gruijl FR, Boland GJ et al (2002) IL-1β gene polymorphisms influence hepatitis B vaccination. Vaccine 20:3193-3196
35. Höhler T, Reuss E, Freitag CM, Schneider PM (2005) A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology 42:72-76
36. Sleijffers A, Yucesoy B, Kashon M, Garssen J, De Gruijl FR, Boland GJ et al (2003) Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination. J Immunol 170:3423-3428. doi: 0022-1767/03/02.00
37. Cheong JY, Cho SW, Oh B, Kimm K, Lee KM, Shin SJ et al (2010) Association of interleukin-18 gene polymorphisms with hepatitis B virus clearance. Dig Dis Sci 55:1113-1119. doi: 10.1007/s10620-009-0819-z
38. Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y et al (2011) Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 31:1118-1126. doi: 10.1111/j.1478-3231.2011. 02507
39. Xia Q, Zhou L, Liu D, Chen Z, Chen F (2011) Relationship between TNF- gene promoter polymorphisms and outcomes of hepatitis B virus infections: a meta-analysis. PLoS One 6:e19606. doi: 10.1371/journal.pone. 0019606
40. Zhang TC, Pan FM, Zhang LZ, Gao YF, Zhang ZH, Gao J et al (2011) A meta-analysis of the relation of polymorphism at sites -1082 and -592 of the IL-10 gene promoter with susceptibility and clearance to persistent hepatitis B virus infection in the Chinese population. Infection 39:21-37
41. Shin HD, Park BL, Cheong HS, Yoon JH, Kim YJ, Lee HS (2007) SPP1 polymorphisms associated with HBV clearance and HCC occurrence. Int J Epidemiol 36:1001-1008. doi: 10.1093/ije/dym093
42. Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L (2012) Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population. Int J Immunogenet 39:346-352. doi: 10.1111/j.1744-313X.2012.01097
43. Chedid MG, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar M, Deulofeut R et al (1997) Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum Immunol 58:42-51
44. Kardar GA, Jeddi-Tehrani M, Shokri F (2002) Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine. Scand J Immunol 55:311-314
45. Vingerhoets J, Vanham G, Kestens L, Penne G, Leroux-Roels G, Gigase P (1994) Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol Lett 39:163-168
46. Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K et al (1999) Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 162:3088-3095. doi: 0022-1767/99/02.00
47. Ishizuka T, Nitta K, Yokoyama T, Hayashi T, Futatsuyama K, Kimata N et al (2002) Increased serum levels of interleukin-12 may be associated with Th1 differentiation in hemodialysis patients. Nephron 90:503-504. doi: 0028-2766/02/0904-050318.50/0
48. Lonnemann G, Novick D, Rubinstein M, Dinarello CA (2003) Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin Nephrol 60:327-334
49. Nakagawa S (2004) A farewell to Bonferroni: the problems of low statistical power and publication bias. Behav Ecol 15:1044-1045. doi: 10.1093/beheco/arh107
50. Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L, Crepaldi M et al (1996) Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 72:536-543 0028-2766/96/0724-053610.00/0
51. Shatat HZ, Kotkat AM, Farghaly AG (2000) Immune response to hepatitis B vaccine in haemodialysis patients. J Egypt Public Health Assoc 75:257-2575
52. Alavian SM, Tabatabaei SV (2010) The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. Vaccine 28:3773-3777. doi: 10.1016/j.vaccine.2010.03.038
53. Douvin C, Simon D, Charles MA, Deforges L, Bierling P, Lehner V et al (1997) Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 20:148-151
54. Cockcroft A, Soper P, Insall C, Kennard Y, Chapman S, Gooch C et al (1990) Antibody response after hepatitis B immunisation in a group of health care workers. Br J Ind Med 47:199-202
55. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J (1996) Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 16:95-97
56. Hennig BJ, Fielding K, Broxholme J, Diatta M, Mendy M, Moore C et al (2008) Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One 3:e1898. doi: 10.1371/journal.pone.0001898
57. Du DW, Jia ZS, Li GY, Zhou YY (2003) HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection. World J Gastroenterol 9:108-111
58. Zeuzem S, Carreño V (2001) Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 52:181-188 PII: S0166-3542(01)00183-8
59. Lada O, Benhamou Y, Poynard T, Thibault V (2006) Coexistence of hepatitis B surface antigen (HBs Ag) and Anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J Virol March 80:2968-2975. doi: 10.1128/JVI.80.6.2968-2975.2006
60. Kohno H, Inoue T, Tsuda F, Okamoto H, Akahane Y (1996) Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. J Gen Virol 77:1825-1831. doi: 10.1099/0022-1317-77-8-1825
61. Chan TM (2010) Hepatitis B and renal disease. Curr Hepat Rep 9:99-105. doi: 10.1007/s11901-010-0042-6
62. Grzegorzewska AE, Kurzawska-Firlej D, Świderski A, de Mezer-Dambek M, Frankiewicz D, Zaremba-Drobnik D et al (2008) Infections with hepatitis B virus in hemodialysis units of Wielkopolska. Przegl Epidemiol 62:29-37
63. Blumberg BS (1979) Sex differences in response to hepatitis B virus I History. Arthritis Rheum 22:1261-1266
64. London WT, Drew JS (2013) Sex differences in response to hepatitis B infection among patients receiving chronic dialysis treatment. HIV Clin Trials 14:17-20
65. Karaosmanoglu HK, Aydin OA, Nazlican O (2011) Isolated anti-HBc among HIV-infected patients in Istanbul, Turkey. Vaccine 29:1721-1726. doi: 10.1016/j.vaccine.2010.11.044
66. Sun HY, Lee HC, Liu CE, Yang CL, Su SC, Ko WC et al (2010) Factors associated with isolated anti-hepatitis B core antibody in HIV-positive patients: impact of compromised immunity. J Viral Hepat 17:578-587
67. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D (2007) Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 68:228-234
68. Barałkiewicz G, Juszczyk J, Grzegorzewska A, Czarnecki R (1996) The results of the vaccination against hepatitis B ('Engerix B') in dialysed uaemic patients [article in Polish]. Hepatologia Pol 3:11-14